View Filing Data

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2017	Mar. 27, 2018	Jun. 30, 2017
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	FY
Entity Registrant Name	EYENOVIA, INC.
Entity Central Index Key	0001682639
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	No
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 51,000,000
Trading Symbol	EYEN
Entity Common Stock, Shares Outstanding		9,936,771

Balance Sheets - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Current Assets:
Cash	$ 5,249,511	$ 3,387,288
Prepaid expenses and other current assets	37,149	2,335
Total Current Assets	5,286,660	3,389,623
Property and equipment, net	27,960	43,192
Deferred offering costs	328,700	0
Total Assets	5,643,320	3,432,815
Current Liabilities:
Accounts payable	246,384	302,031
Accrued expenses and other current liabilities	306,263	121,703
Total Current Liabilities	552,647	423,734
Commitments and contingencies (Note 7)
Stockholders' Equity:
Common stock, $0.0001 par value, 60,000,000 shares authorized as of December 31, 2017 (see Note 9), 2,566,530 and 2,266,667 shares issued and outstanding as of December 31, 2017 and 2016, respectively	257	227
Additional paid-in capital	24,351,138	17,139,651
Accumulated deficit	(19,261,186)	(14,131,199)
Total Stockholders' Equity	5,090,673	3,009,081
Total Liabilities and Stockholders' Equity	5,643,320	3,432,815
Series A Convertible Preferred Stock [Member]
Stockholders' Equity:
Preferred Stock	293	323
Total Stockholders' Equity	293	323
Series A-2 Convertible Preferred Stock [Member]
Stockholders' Equity:
Preferred Stock	79	79
Total Stockholders' Equity	79	79
Series B Convertible Preferred Stock [Member]
Stockholders' Equity:
Preferred Stock	92	0
Total Stockholders' Equity	$ 92	$ 0

Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	36,000,000
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	60,000,000
Common Stock, Shares, Issued	2,566,530	2,266,667
Common Stock, Shares, Outstanding	2,566,530	2,266,667
Series A Convertible Preferred Stock [Member]
Preferred Stock Designated Shares	20,000,000
Preferred Stock, Shares Issued	2,932,431	3,232,294
Preferred Stock, Shares Outstanding	2,932,431	3,232,294
Preferred Stock, Liquidation Preference, Value	$ 10,996,014	$ 12,121,102
Series A-2 Convertible Preferred Stock [Member]
Preferred Stock Designated Shares	5,714,286
Preferred Stock, Shares Issued	788,827	788,827
Preferred Stock, Shares Outstanding	788,827	788,827
Preferred Stock, Liquidation Preference, Value	$ 4,141,338	$ 4,141,338
Series B Convertible Preferred Stock [Member]
Preferred Stock Designated Shares	10,000,000
Preferred Stock, Shares Issued	918,983	0
Preferred Stock, Shares Outstanding	918,983	0
Preferred Stock, Liquidation Preference, Value	$ 6,409,657	$ 0

Statements of Operations - USD ($)	12 Months Ended
Statements of Operations - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Operating Expenses:
Research and development	$ 3,816,732	$ 2,966,165
General and administrative	1,315,635	568,775
Total Operating Expenses	5,132,367	3,534,940
Loss From Operations	(5,132,367)	(3,534,940)
Other Income:
Interest income	2,380	1,497
Net Loss	$ (5,129,987)	$ (3,533,443)
Net Loss Per Share
- Basic and Diluted	$ (2.19)	$ (1.56)
Weighted Average Number of Common Shares Outstanding
- Basic and Diluted	2,344,712	2,266,667

Statements of Changes in Stockholders’ Equity - USD ($)

Total

Series A Convertible Preferred Stock [Member]

Series A-2 Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Common Stock [Member]

Additional Paid-In Capital [Member]

Accumulated Deficit [Member]

Balance at Dec. 31, 2015

$ 2,398,496

$ 323

$ 0

$ 227

$ 12,995,702

$ (10,597,756)

Balance (in shares) at Dec. 31, 2015

3,232,294

2,266,667

Stock-based compensation

2,690

$ 0

2,690

Issuance convertible preferred stock, net of issuance costs

4,141,338

$ 0

$ 79

$ 0

4,141,259

Issuance convertible preferred stock, net of issuance costs (in shares)

788,827

Net loss

(3,533,443)

$ 0

(3,533,443)

Balance at Dec. 31, 2016

3,009,081

$ 323

$ 79

$ 0

$ 227

17,139,651

(14,131,199)

Balance (in shares) at Dec. 31, 2016

3,232,294

788,827

2,266,667

Issuance of warrant

431,574

$ 0

431,574

Stock-based compensation

412,312

Issuance convertible preferred stock, net of issuance costs

^[1]

6,367,693

$ 0

$ 92

$ 0

6,367,601

Issuance convertible preferred stock, net of issuance costs (in shares)

^[1]

918,983

Conversion of Series A convertible preferred stock into common stock

$ (30)

$ 0

$ 30

Conversion of Series A convertible preferred stock into common stock (in shares)

(299,863)

299,863

Net loss

(5,129,987)

$ 0

(5,129,987)

Balance at Dec. 31, 2017

$ 5,090,673

$ 293

$ 79

$ 92

$ 257

$ 24,351,138

$ (19,261,186)

Balance (in shares) at Dec. 31, 2017

2,932,431

788,827

918,983

2,566,530

[1]	Includes gross proceeds of $6,409,651, less issuance costs of $41,958.

Statements of Changes in Stockholders’ Equity (Parenthetical)	12 Months Ended
	Dec. 31, 2017 USD ($)
Proceeds Of Stock Issued During Period Gross	$ 6,409,651
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	$ 41,958

Statements of Cash Flows - USD ($)	12 Months Ended
Statements of Cash Flows - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Cash Flows From Operating Activities
Net loss	$ (5,129,987)	$ (3,533,443)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	25,466	12,802
Stock-based compensation	412,312	2,690
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(34,814)	310,498
Accounts payable	(55,647)	55,509
Accrued expenses and other current liabilities	51,560	(51,598)
Net Cash Used In Operating Activities	(4,731,110)	(3,203,542)
Cash Flows From Investing Activities
Purchases of property and equipment	(10,234)	(43,119)
Net Cash Used In Investing Activities	(10,234)	(43,119)
Cash Flows From Financing Activities
Payment of initial public offering costs	(195,700)	0
Proceeds from sale of warrant	431,574	0
Net Cash Provided By Financing Activities	6,603,567	4,141,338
Net Increase in Cash	1,862,223	894,677
Cash - Beginning of Period	3,387,288	2,492,611
Cash - End of Period	5,249,511	3,387,288
Supplemental Disclosure of Non-Cash Financing Activities
Accrual of intitial public offering costs	133,000	0
Conversion of convertible preferred stock into common stock	30	0
Series A-2 Convertible Preferred Stock [Member]
Cash Flows From Operating Activities
Net loss	0	0
Cash Flows From Financing Activities
Proceeds from sale of Convertible Preferred Stock	0	4,141,338
Series B Convertible Preferred Stock [Member]
Cash Flows From Operating Activities
Net loss	0	0
Cash Flows From Financing Activities
Proceeds from sale of Convertible Preferred Stock	6,409,651	0
Payment of Series B Convertible Preferred Stock issuance costs	$ (41,958)	$ 0

Business Organization and Nature of Operations

12 Months Ended

Dec. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

Note 1 – Business Organization and Nature of Operations

Eyenovia, Inc. (“Eyenovia” or the “Company”) was organized as a corporation under the laws of the State of Florida on March 12, 2014 under the name, PGP Holdings V, Inc. On May 5, 2014, PGP Holdings V, Inc. changed its name to Eyenovia, Inc. On October 6, 2014, Eyenovia, Inc. reincorporated in the State of Delaware by merging into Eyenovia, Inc., a Delaware corporation.

Eyenovia is a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-doses (6–8 µL) of active pharmaceutical ingredients (or “micro-therapeutics”) topically to the eye. This disruptive micro-dosing technology has the potential to replace traditional macro-dosing applications (e.g. conventional eye droppers), that routinely overdoses or under-doses the topical administration of ophthalmic therapeutics.

Effective January 8, 2018, pursuant to authority granted by the stockholders of the Company, the Company implemented a 1-for-3.75 reverse split of the Company’s issued and outstanding common stock and preferred stock (the “Reverse Split”). The number of authorized shares remains unchanged. All share and per share information has been retroactively adjusted to reflect the Reverse Split for all periods presented, unless otherwise indicated.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

Note 2 – Summary of Significant Accounting Policies

Liquidity and Financial Condition

The Company incurred net losses of $5,129,987 and $3,533,443 for the years ended December 31, 2017 and 2016, respectively. At December 31, 2017, the Company’s working capital and accumulated deficit were $4,734,013 and $19,261,186, respectively. The Company has not yet generated revenues or achieved profitability and it is expected that its research and development and general and administrative expenses will continue to increase and, as a result, the Company will eventually need to generate significant product revenues to achieve profitability. Subsequent to December 31, 2017, the Company raised aggregate net proceeds of approximately $24.5 million in connection with its initial public offering (“IPO”). See Note 10 – Subsequent Events for additional details.

The Company believes its current cash on hand is sufficient to meet its operating and capital requirements for at least the next fifteen months from the date these financial statements are issued. Thereafter, the Company may need to raise further capital, through the sale of additional equity or debt securities, to support its future operations. The Company’s operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Company’s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company’s ability to successfully commercialize its products and services, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement our product and service offerings. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.

Use of Estimates

Preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, establishment of valuation allowances for deferred tax assets, stock-based compensation, the recoverability and useful lives of long-lived assets and the recovery of deferred costs. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates.

Summary of Significant Accounting Policies — Stock-Based Compensation for additional discussion of the use of estimates in estimating the fair value of the Company’s common stock.

Cash

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents in the financial statements. As of December 31, 2017 and 2016, the Company had no cash equivalents.

The Company has cash deposits in several financial institutions which, at times, may be in excess of Federal Deposit Insurance Corporation (“FDIC”) insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. On December 31, 2017 and 2016, the Company had cash balances in excess of FDIC insurance limits of $4,999,511 and $3,137,288, respectively.

Property and Equipment, Net

Property and equipment are stated at cost, net of accumulated depreciation, which is recorded commencing at the in-service date using the straight-line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives, which range from 2 to 5 years. Leasehold improvements are amortized over the lesser of (a) the useful life of the asset; or (b) the remaining lease term. Maintenance and repairs are charged to operations as incurred. The Company capitalizes costs attributable to the betterment of property and equipment when such betterment extends the useful life of the assets.

Deferred Offering Costs

Deferred offering costs, which primarily consist of direct, incremental professional fees incurred in connection with the Company’s IPO as well as other private equity offerings are capitalized as non-current assets on the balance sheet. As of December 31, 2017 and 2016, there were deferred offering costs in the amount of $328,700 and $0, respectively. Upon the closing of the IPO, the deferred offering costs will be offset against the proceeds of the IPO.

Impairment of Long-lived Assets

The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. An impairment would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. The Company did not record any impairment losses during the years ended December 31, 2017 and 2016.

Preferred Stock

The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders’ equity.

Convertible Instruments

The Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for in accordance with Topic 815 of the Financial Accounting Standards Board ("FASB") Accounting Standards Codification (“ASC”). The accounting treatment of derivative financial instruments requires that the Company record embedded conversion options and any related freestanding instruments at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period at each balance sheet date. The Company reassesses the classification of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification. Embedded conversion options and any related freestanding instruments are recorded as a discount to the host instrument.

If the instrument is determined to be a derivative liability, the Company then evaluates for the existence of a beneficial conversion feature by comparing the market price of the Company’s common stock as of the commitment date to the effective conversion price of the instrument.

Fair Value of Financial Instruments

The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

Level 1 — quoted prices in active markets for identical assets or liabilities;

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable; and

Level 3 — inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).

The carrying amounts of the Company’s financial instruments, such as cash, accounts payable, accrued expenses and other current liabilities approximate fair values due to the short-term nature of these instruments.

Income Taxes

The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse.

The Company utilizes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.

Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s financial statements as of December 31, 2017 and 2016. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date.

The Company’s policy is to classify assessments, if any, for tax-related interest as interest expense and penalties as general and administrative expenses in the statements of operations.

Research and Development

Research and development expenses are charged to operations as incurred. The Company records prepaid expenses on its balance sheet for the payment of research and development expenses in advance of services being provided.

Stock-Based Compensation

The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Awards granted to directors are treated on the same basis as awards granted to employees. Upon the exercise of an option, the Company issues new shares of common stock out of its authorized shares.

During the year ended December 31, 2016, the fair value of the Company’s common stock was based on an analysis completed by management that considered the cash sales prices of the convertible preferred stock as well as the relative characteristics, rights and privileges of the convertible preferred stock as compared to the common stock. During the year ended December 31, 2017, the Company obtained a third-party 409A valuation of its common stock, which was also considered in management’s estimation of the value of the equity instruments issued during that period. This third-party valuation was done in accordance with the guidance outlined in the American Institute of Certified Public Accountants’ Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. The estimates used by management are considered highly complex and subjective. Subsequent to the IPO, the shares began trading on January 24, 2018, which is the date the use of such estimates is no longer necessary to determine the fair value of the common stock.

The independent analysis utilized the Backsolve method since this method is generally considered the most reliable and is recommended by the American Institute of Certified Public Accountants’ Accounting and Valuation Guide, Valuation of Privately Held Company Equity Securities Issued as Compensation. In addition, the method utilizes the economics from a direct transaction in our securities in determining the fair market value. This method utilizes the Black Scholes option pricing model which allocated a probability weighted equity value to the Company’s Series A- 2 preferred stock. The Series A-2 preferred stock was utilized since it included new investors, was considered at arms’ length and closed in the fourth quarter of 2016.

The March 2017 independent appraisal utilized the option pricing method, or OPM, as the most reliable method with the following steps being applied:

⋅

Establishment of total enterprise or equity value;

⋅

Analysis of equity rights for each class of security;

⋅

Selection of appropriate model for valuation purposes;

⋅

Determination of key valuation inputs; and

⋅

Computation of the fair value of the subject security.

Under the OPM, it was determined the Company’s common stock had an allocated per share value of $3.23 per share. As a private company, the analysis provided for a discount for lack of marketability of 40% resulting in a fair market value of the Company’s common stock of $1.95 per share as of March 2017 based upon the independent appraisal. This price represents the same exercise price of the stock options the Company granted in July 2017 as management determined no material events or conditions occurred at the Company that would have a material effect on this per share price.

Net Loss Per Common Share

Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock.

The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:

	December 31,
	2017		2016
Options		1,684,416		786,667
Warrant		61,875		-
Series A Convertible Preferred Stock		2,932,431		3,232,294
Series A-2 Convertible Preferred Stock		788,827		788,827
Series B Convertible Preferred Stock		918,983		-
Total potentially dilutive shares		6,386,532		4,807,787

Subsequent Events

The Company has evaluated subsequent events through the date which the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed.

Recently Issued Accounting Pronouncements

In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. ASU 2016-02 will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating ASU 2016-02 and its impact on its financial position, results of operations, and cash flows.

In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments,” (“ASU 2016-15”). The new standard will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. The new standard is effective for fiscal years beginning after December 15, 2018. We will require adoption on a retrospective basis unless it is impracticable to apply, in which case we would be required to apply the amendments prospectively as of the earliest date practicable. The Company is currently evaluating ASU 2016-15 and its impact on its financial position, results of operations, and cash flows.

In May 2017, the FASB issued ASU No. 2017-09, “Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting” (“ASU 2017-09”). ASU 2017-09 provides clarity on the accounting for modifications of stock-based awards. ASU 2017-09 requires adoption on a prospective basis in the annual and interim periods for our fiscal year ending December 15, 2018 for share-based payment awards modified on or after the adoption date. The Company is currently evaluating ASU 2017-09 and its impact on its financial position, results of operations, and cash flows.

In July 2017, the FASB issued ASU No. 2017-11, “Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815) - Accounting for Certain Financial Instruments with Down Round Features” (“ASU 2017-11”). Equity-linked instruments, such as warrants and convertible instruments may contain down round features that result in the strike price being reduced on the basis of the pricing of future equity offerings. Under ASU 2017-11, a down round feature will no longer require a freestanding equity-linked instrument (or embedded conversion option) to be classified as a liability that is remeasured at fair value through the income statement (i.e. marked-to-market). However, other features of the equity-linked instrument (or embedded conversion option) must still be evaluated to determine whether liability or equity classification is appropriate. Equity classified instruments are not marked-to-market. For earnings per share ("EPS") reporting, the ASU requires companies to recognize the effect of the down round feature only when it is triggered by treating it as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted, including adoption in any interim period. The Company is currently evaluating ASU 2017-11 and its impact on its financial position, results of operations, and cash flows.

Recently Adopted Accounting Pronouncements

In March 2016, the FASB issued ASU No. 2016-09, “Compensation – Stock Compensation (Topic 718)” (“ASU 2016-09”). ASU 2016-09 requires an entity to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2017, with early adoption permitted. The adoption of this standard did not have a material impact on the Company’s financial position, results of operations and cash flows.

Prepaid Expenses and Other Current Assets

12 Months Ended

Dec. 31, 2017

Prepaid Expense and Other Assets [Abstract]

Prepaid Expenses and Other Current Assets Disclosure [Text Block]

Note 3 – Prepaid Expenses and Other Current Assets

As of December 31, 2017 and 2016, prepaid expenses and other current assets consisted of the following:

	December 31,
	2017		2016
Prepaid research and development expenses	$	28,932	$	-
Prepaid patent expense		7,833
Prepaid insurance expenses		383		2,335
Total prepaid expenses and other current assets	$	37,149	$	2,335

Property and Equipment, Net

12 Months Ended

Dec. 31, 2017

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

Note 4 – Property and Equipment, Net

As of December 31, 2017 and 2016, property and equipment consisted of the following:

	December 31,
	2017		2016
Equipment	$	34,979	$	24,745
Leasehold improvements		40,000		40,000
		74,979		64,745
Less: accumulated depreciation and amortization		(47,019)		(21,553)
Property and equipment, net	$	27,960	$	43,192

Depreciation and amortization expense was $25,466 and $12,802 for the years ended December 31, 2017 and 2016, respectively, which is included within research and development expenses in the statements of operations.

Accrued Expenses and Other Current Liabilities

12 Months Ended

Dec. 31, 2017

Payables and Accruals [Abstract]

Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]

Note 5 – Accrued Expenses and Other Current Liabilities

As of December 31, 2017 and 2016, accrued expenses and other current liabilities consisted of the following:

	December 31,
	2017		2016
Accrued research and development expenses	$	120,455	$	61,000
Accrued legal expenses		-		37,597
Accrued rent expense		-		18,590
Accrued professional services		41,831		-
Accrued offering costs		133,000		-
Other		10,977		4,516
Total accrued expenses and other current liabilities	$	306,263	$	121,703

Income Taxes

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

Note 6 – Income Taxes

The income tax (provision) benefit consists of the following:

	For The Years Ended
	December 31,
	2017		2016
Federal:
Current	$	-	$	-
Deferred		235,473		1,287,931
State and local:				-
Current		-		-
Deferred		80,301		151,521
		315,774		1,439,452
Change in valuation allowance		(315,774)		(1,439,452)
Income tax (provision) benefit	$	-	$	-

A reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows:

	For The Years Ended
	December 31,
	2017			2016
Tax benefit at federal statutory rate		34.0	%		34.0	%
State income taxes, net of federal benefit		4.0	%		4.0	%
Incremental research and development credits		6.3	%		2.7	%
Prior period adjustments and other		(8.1)	%		0.0	%
Effect of tax rate changes		(30.0)	%		0.0	%
Change in valuation allowance		(6.2)	%		(40.7)	%
Effective income tax rate		0.0	%		0.0	%

The tax effects of temporary differences that give rise to deferred tax assets and liabilities are presented below:

	December 31,
	2017		2016
Deferred Tax Assets:
Net operating loss carryforwards	$	2,588,641	$	2,742,397
Stock-based compensation		347,977		333,066
Research & development tax credits		526,134		201,840
Intangible assets		364,508		234,183
Gross deferred tax assets		3,827,260		3,511,486

Valuation allowance		(3,827,260)		(3,511,486)

Deferred tax assets, net of valuation allowance	$	-	$	-

Changes in valuation allowance	$	(315,774)	$	(1,439,452)

The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not likely, a valuation allowance is established. Based upon the Company’s history of losses since inception, management believes that it is more likely than not that future benefits of deferred tax assets will not be realized.

At December 31, 2017 and 2016, the Company estimates that it has approximately $11,000,000 and $7,200,000, respectively, of federal net operating losses that may be available to offset future taxable income. The net operating loss carry forwards, if not utilized, will expire from 2034 to 2037 for federal purposes. At December 31, 2017, the Company estimates that it has approximately $2,000,000 of New York State net operating losses that may be available to offset future taxable income. In accordance with Section 382 of the Internal Revenue Code, the usage of the Company’s net operating loss carry forwards could become subject to annual limitations if there are greater than 50% ownership changes.

The Company files income tax returns in the U.S. federal jurisdiction, the State of New York and the state of Florida (where the Company filed its final return in 2015), which remain subject to examination by the various taxing authorities beginning with the tax year ended December 31, 2014.

The Tax Cuts and Jobs Act (the "Act") was enacted in December 2017. Among other things, the primary provision of Tax Reform impacting the Company is the reduction to the U.S. corporate income tax rate from 35% to 21%. The change in tax law required the Company to remeasure existing net deferred tax assets using the lower rate in the period of enactment resulting in an income tax expense of approximately $1.5 million which is fully offset by the corresponding tax benefit of $1.5 million from the reduction in the valuation allowance in the year ended December 31, 2017. There were no specific impacts of Tax Reform that could not be reasonably estimated which the Company accounted for under the prior tax law. However, further analysis of the estimates and further guidance on the application of the law could result in additional revisions during the allowable one-year measurement period, as outlined in Staff Accounting Bulletin No. 118.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

Note 7 – Commitments and Contingencies

Operating Leases

On September 15, 2016, the Company entered into a lease agreement to lease 953 square feet of space located in Reno, NV with respect to its research and development activities. The monthly base rent is $3,895 per month over the term of the lease. The lease expires on September 14, 2018 and is subject to an extension at the option of the Company at a fixed rental rate for an additional 2-year period. The Company’s rent expense amounted to $45,678 and $18,590 for the years ended December 31, 2017 and 2016, respectively. See Note 8 — Related Party Transactions.

Future minimum payments under this operating lease agreement are as follows:

For the Year Ending
December 31,	Amount
2018		33,108
	$	33,108

Litigations, Claims and Assessments

In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.

The Company, its Chief Executive Officer and members of its Board of Directors are named as defendants in a legal proceeding filed in the United States District Court for the District of New Jersey on September 2, 2014 that has not yet been fully resolved in connection with the Company’s Asset Purchase Agreement with Corinthian Ophthalmic, Inc. (“Corinthian”). A shareholder of Corinthian, alleging a fraudulent transfer, is seeking to recover the purchase price of its Corinthian shares and other damages in aggregate amount of approximately $1.1 million. The parties are not close to agreement on a settlement, and although further discussions may occur, the parties are prepared to proceed to trial. The court conducted a pretrial conference on January 22, 2018 and entered a final pretrial order on January 23, 2018. The order provided, among other things, for a final pretrial conference to be conducted on August 15, 2018 to address objections to expert witnesses’ opinions and testimony, with objections to be submitted by July 18, 2018 and responses by August 1, 2018. Trial briefs, requests for jury instructions, and proposed voir dire questions are due on August 30, 2018. The trial is scheduled for September 10, 2018. The Company is indemnified by Corinthian and Corinthian’s applicable insurance policy provides coverage of $10 million, such that the Company does not expect to incur a material loss as a result of this litigation and, as a result, did not record a loss contingency as of December 31, 2017 or 2016, respectively.

Related Party Transactions

12 Months Ended

Dec. 31, 2017

Note 8 – Related Party Transactions

The Company’s Chief Executive Officer as well as a member of its Board of Directors are both partners in Private Medical Equity, Inc. (“PME”). The Company and PME are parties to a consulting agreement dated November 4, 2014 that provides for the payment of $33,200 per month to PME in consulting fees for general management and strategy services. Any time spent by PME in excess of the specified amount is billed separately. During the years ended December 31, 2017 and 2016, the Company incurred $329,400 and $398,400, respectively, related to the agreement, of which, $176,344 and $318,720, respectively, was included within research and development expenses and $152,656 and $79,680, respectively, was included within general and administrative expenses on the condensed statements of operations. On August 1, 2017, the agreement was terminated and the Company’s Chief Executive Officer was employed full time by the Company. The Board member now bills the Company through a separate consulting agreement dated July 6, 2017 that is discussed below.

A company that beneficially owns greater than 5% of the Company’s common stock has a consulting agreement with the Company for research and development services. During the years ended December 31, 2017 and 2016, the Company recognized $0 and $366,209, respectively, related to the agreement, which was included within research and development expenses on the statements of operations.

Since July 2016, the Company pays $3,000 per month to a company controlled by a member of its Board of Directors for office space in New York, New York for its Chief Executive Officer. During the years ended December 31, 2017 and 2016, the Company recorded rent expense of $36,000 and $18,000, respectively, related to the office space.

A company in which a member of the Company’s Board of Directors is part owner is a party to a consulting agreement with the Company dated July 6, 2017 that provides for the payment of $9,567 per month, and $250 per hour for any additional work, for advisory services performed by such director. During the year ended December 31, 2017, the Company incurred $85,835 related to the agreement which was included within general and administrative expenses on the statement of operations.

On July 6, 2017, the Company entered into an engagement letter with its Vice President of Research and Development (“VP of R&D”). Pursuant to the terms of the engagement letter, starting on August 1, 2017, the VP of R&D was to provide service to the Company as a non-employee on a part-time basis in exchange for $9,167 per month and $175 per hour for any additional work. On July 7, 2017, the VP of R&D was granted options to purchase 100,264 shares of common stock at an exercise price of $1.95 per share that vest in equal monthly installments over 36 months starting from the date of grant. The options had a grant date fair value of $173,900. On August 16, 2017, the VP of R&D changed from a non-employee to an employee of the Company but remained employed on a part-time basis at the same compensation rate. Subsequent to December 31, 2017, the VP of R&D’s salary was increased to $165,000 per year in connection with the increase from two (2) to three (3) days of work per week. The following are related party transactions involving the VP of R&D:

The VP of R&D owns a company that entered into a lease agreement with the Company on September 15, 2016 to lease 953 square feet of space located in Reno, NV with respect to its research and development activities. The monthly base rent is $3,895 per month over the term of the lease and the security deposit is $3,895. The lease expires on September 14, 2018 and is subject to an extension at the option of the Company at a fixed rental rate for an additional 2-year period. The Company made $40,000 of leasehold improvements related to this lease which are included on the balance sheet. The Company’s rent expense amounted to $45,678 and $18,590 for the years ended December 31, 2017 and 2016, respectively.

The VP of R&D is the sole owner and President of a company that performs contract engineering services for the Company. During the years ended December 31, 2017 and 2016, the Company recognized research and development expense of $1,155,500 and $1,427,958, respectively, related to services provided by such vendor. As of December 31, 2017, the Company had a liability of $94,998 to the vendor and $9,906 related to expenses incurred by the VP of R&D.

During 2015, the Company entered into a license agreement with Senju Pharmaceutical Co., Lt. (“Senju”) whereby the Company agreed to grant to Senju an exclusive, royalty-bearing license for its micro-dose product candidates for Asia to sublicense, develop, make, have made, manufacture, use, import, market, sell, and otherwise distribute the micro-dose product candidates. In consideration for the license, Senju agreed to pay to Eyenovia five percent (5%) royalties for the term of the license agreement. The agreement shall continue in full force and effect, on a country-by-country basis, until the latest to occur of: (i) the tenth (10th) anniversary of the first commercial sale of a micro-dose product candidate in Asia; or (ii) the expiration of the licensed patents. As of the date of filing, there had been no commercial sales of a micro-dose product candidate in Asia such that no royalties had been earned. Senju is owned by the family of a member of the Company’s Board of Directors and both beneficially own greater than 5% of the Company’s common stock.

Stockholders’ Equity

12 Months Ended

Dec. 31, 2017

Equity [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

Note 9 – Stockholders’ Equity

Reverse Stock Split

Authorized Capital

As of December 31, 2017, the Company was authorized to issue 60,000,000 shares of common stock, par value of $0.0001 per share, and 36,000,000 shares of preferred stock, par value of $0.0001 per share. The holders of the Company’s common stock are entitled to one vote per share. As of December 31, 2017, the preferred stock was designated as follows: 20,000,000 shares designated as Series A Convertible Preferred Stock; 5,714,286 shares designated as Series A-2 Convertible Preferred Stock; and 10,000,000 shares designated as Series B Convertible Preferred Stock.

On January 29, 2018, in connection with its IPO and the conversion of all then existing preferred stock into common stock, the Company filed its Third Amended and Restated Certificate of Incorporation (the “Third Amendment”) with the Secretary of State of the State of Delaware, effective the same day. Pursuant to the Third Amendment, the Company is authorized to issue 90,000,000 shares of common stock and 6,000,000 shares of preferred stock. The holders of the Company’s common stock are entitled to one vote per share. No shares of preferred stock were designated. Pursuant to the Third Amendment, the Board of Directors is empowered, without stockholder approval, to issue preferred stock with dividend, liquidation, redemption, voting or other rights.

2014 Equity Incentive Plan

The Company’s 2014 Equity Incentive Plan (“2014 Plan”) provides for the issuance of incentive stock options, nonstatutory stock options, rights to purchase common stock, stock appreciation rights, restricted stock and restricted stock units to employees, directors and consultants of the Company and its affiliates. The 2014 Plan became effective on December 14, 2014 and shall terminate on the tenth (10th) anniversary of the effective date. The 2014 Plan requires the exercise price of stock options to be greater than or equal to the fair value of the Company’s common stock on the date of grant. As of December 31, 2017, there were 48,917 shares available for future issuance under the 2014 Plan.

On January 5, 2018, the Company’s Board of Directors and shareholders approved an amendment to the Company’s 2014 Plan to increase the number of shares of common stock authorized under the 2014 Plan from 1,733,333 shares to 1,866,667 shares.

Series A and Series A-2 Convertible Preferred Stock

On October 6, 2016, the Company sold an aggregate of 788,827 shares of Series A-2 Convertible Preferred Stock to investors at a price of $5.25 per share for aggregate proceeds of $4,141,338.

On July 6, 2017, the Company’s Board of Directors adopted, and the Company’s stockholders approved, the Second Amendment to the Company’s Certificate of Incorporation (the “Second Amendment”). Pursuant to the Second Amendment, in the event that any holder of shares of Series A Convertible Preferred Stock or Series A-2 Convertible Preferred Stock (collectively, the “Series A/A-2 Preferred Stock”) does not participate in a subsequent financing (as defined in the Second Amendment) by purchasing in the aggregate, in such subsequent financing, at least 75% of such holder’s pro rata amount, then each share of Series A/A-2 Preferred Stock held by such holder shall automatically be converted into common stock concurrently with the consummation of such subsequent financing. Such conversion is referred to as a “Special Mandatory Conversion.”

On September 27, 2017, in connection with the sale of Series B Convertible Preferred Stock, holders of an aggregate of 299,863 shares of Series A Convertible Preferred Stock did not participate in such financing by purchasing at least 75% of such holder’s pro rata amount. As a result, the Special Mandatory Conversion of the Series A/A-2 Preferred Stock was triggered and, accordingly, such shares of Series A Convertible Preferred stock were automatically converted into an aggregate of 299,863 shares of common stock.

The preferred stock did not contain a redemption provision and an overall analysis of its features performed by the Company determined that it was more akin to equity and therefore, has been classified within stockholders’ equity on the balance sheet. While the embedded conversion option (“ECO”) was subject to an anti-dilution price adjustment, since the ECO was clearly and closely related to the equity host, it was not required to be bifurcated and accounted for as a derivative liability under ASC 815. The Company determined that the preferred stock did not contain a beneficial conversion feature, since the conversion price exceeded the estimated fair value of the Company’s common stock as of the commitment date.

The Series A and Series A-2 Convertible Preferred Stock is convertible, at the option of the holder, at any time into shares of common stock on a one-for-one basis. In the event of any issuances by the Company for less than the in-force conversion price, the preferred stock conversion price shall be reduced on a weighted average basis. Each share of preferred stock shall automatically be converted into shares of common stock at the then effective conversion price: (i) immediately prior to the closing of a firm commitment underwritten initial public offering provided that (A) the aggregate offering price, net of underwriters’ discounts and expenses, is at least $2.00 per share of common stock and (B) the aggregate proceeds of such offering are not less than $20,000,000; or (ii) the date specified by written consent or agreement of the holders of at least 75% of the then outstanding shares of preferred stock. See Note 10 – Subsequent Events for additional details.

Series B Convertible Preferred Stock

During the year ended December 31, 2017, the Company sold an aggregate of 918,983 shares of its Series B Convertible Preferred Stock to investors at a price of $6.98 per share for aggregate gross proceeds of $6,409,651. The Company incurred $41,958 of legal costs in connection with the sale, such that the aggregate net proceeds from the sale were $6,367,693.

On November 9, 2017, the Board adopted resolutions ratifying each of the issuances of Series B Convertible Preferred Stock, which were then approved by the Company’s shareholders. On November 13, 2017, the Company filed a certificate of validation with the Delaware Secretary of State in respect of such ratifications, such that, as of that date, the Series B Convertible Preferred Stock was duly authorized, validly issued, fully paid and nonassessable.

The Series B Convertible Preferred Stock is convertible, at the option of the holder, at any time into shares of common stock on a one-for-one basis, subject to certain adjustments. In the event of any issuances by the Company for less than the in-force conversion price, the Series B Convertible Preferred Stock conversion price shall be reduced on a weighted average basis. Each share of Series B Convertible Preferred Stock shall automatically be converted into shares of common stock at the then effective conversion price: (i) immediately prior to the closing of a firm commitment underwritten initial public offering provided that (A) the aggregate offering price, net of underwriters' discounts and expenses, is at least $2.00 per share of common stock and (B) the aggregate proceeds of such offering are not less than $20,000,000; or (ii) the date specified by written consent or agreement of the holders of at least 75% of the then outstanding shares of preferred stock.

The Series B Convertible Preferred did not contain a redemption provision and an overall analysis of its features performed by the Company determined that it was more akin to equity and therefore, has been classified within stockholders’ equity on the balance sheet. While the embedded conversion option (“ECO”) was subject to an anti-dilution price adjustment, since the ECO was clearly and closely related to the equity host, it was not required to be bifurcated and accounted for as a derivative liability under ASC 815. The Company determined that the Series B Convertible Preferred did not contain a beneficial conversion feature, since the conversion price exceeded the estimated fair value of the Company’s common stock as of the commitment date.

See Note 10 – Subsequent Events for additional details.

Stock Warrants

On September 27, 2017, the Company issued a warrant to purchase 61,875 shares of common stock at an exercise price of $6.98 per share to an investor for cash consideration of $431,574, which was included within additional paid-in capital on the balance sheet as of December 31, 2017. The warrant is exercisable any time through September 27, 2027. The warrant was sold to an investor for the amount of the investment in excess of what was permitted to be purchased of Series B Convertible Preferred Stock.

A summary of the warrant activity during the year ended December 31, 2017 is presented below:

					Weighted
			Weighted		Average
			Average		Remaining		Aggregate
	Number of		Exercise		Life		Intrinsic
	Warrants		Price		In Years		Value
Outstanding January 1, 2017		-	$	-
Granted		61,875		6.98
Forfeited		-		-
Outstanding December 31, 2017		61,875	$	6.98		9.7	$	-

Exercisable December 31, 2017		61,875	$	6.98		9.7	$	-

The following table presents information related to warrants as of December 31, 2017:

Warrants Outstanding				Warrants Exercisable
				Weighted
		Outstanding		Average		Exercisable
Exercise		Number of		Remaining Life		Number of
Price		Warrants		In Years		Warrants
	6.98		61,875		9.7		61,875
			61,875		9.7		61,875

Stock Options

In applying the Black-Scholes option pricing model to stock options granted, the Company used the following approximate assumptions:

	For the Year Ended
	December 31,
	2017			2016
Expected term (years)		5.32 - 10.00			10.00
Risk free interest rate		1.95 - 2.39	%		1.53% - 1.83	%
Expected volatility		130	%		131	%
Expected dividends		0.00	%		0.00	%

The Company has computed the fair value of stock options granted using the Black-Scholes option pricing model. Option forfeitures are accounted for at the time of occurrence. The expected term used for options issued to non-employees is usually the contractual life and the expected term used for options issued to employees and directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the “simplified” method to develop an estimate of the expected term of “plain vanilla” employee option grants. The Company does not currently have a trading history to support its historical volatility calculations. Accordingly, the Company is utilizing an expected volatility figure based on a review of the historical volatility of three comparable entities over a period of time equivalent to the expected life of the instrument being valued. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.

The weighted average estimated grant date fair value of the stock options granted for the year ended December 31, 2017 and 2016 was approximately $1.77 and $1.16 per share, respectively.

The Company recorded stock-based compensation expense related to stock options of $412,312 and $2,690 during the year ended December 31, 2017 and 2016, respectively. As of December 31, 2017, there was $1,327,224 of unrecognized stock-based compensation expense, of which, $377,816 related to non-employee grants, which will be recognized over a weighted average period of 2.4 years. Subsequent to December 31, 2017, the Company closed on its IPO at an offering price of $10.00 per share and as of March 27, 2018, the Company’s shares closed at $9.20 per share. The Company’s stock-based compensation expense related to non-employee grants that is recognized subsequent to December 31, 2017 will be materially impacted as a result of the increase in stock price subsequent to December 31, 2017.

A summary of the option activity during the year ended December 31, 2017 is presented below:

					Weighted
			Weighted		Average
			Average		Remaining		Aggregate
	Number of		Exercise		Life		Intrinsic
	Options		Price		In Years		Value
Outstanding January 1, 2017		786,669	$	1.37
Granted		897,747		1.95
Forfeited		-		-
Outstanding December 31, 2017		1,684,416	$	1.68		8.5	$	4,361,825

Exercisable December 31, 2017		920,383	$	1.39		7.6	$	883,675

The following table presents information related to stock options as of December 31, 2017:

Options Outstanding				Options Exercisable
				Weighted
		Outstanding		Average		Exercisable
Exercise		Number of		Remaining Life		Number of
Price		Options		In Years		Options
$	1.24		760,001		7.2		760,001
$	1.95		897,747		9.5		152,465
$	5.25		26,668		8.8		7,917
			1,684,416		7.6		920,383

Subsequent Events

12 Months Ended

Dec. 31, 2017

Subsequent Events [Abstract]

Subsequent Events [Text Block]

Note 10 – Subsequent Events

Initial Public Offering

On January 29, 2018, the Company consummated its IPO of 2,730,000 shares of its common stock at an offering price of $10.00 per share, generating $27.3 million and $24.5 million in gross and net proceeds, respectively. Underwriting discounts, commissions and other offering expenses were approximately $2.8 million, a portion of which is included within deferred offering costs on the balance sheet as of December 31, 2017.

Conversion of Preferred Stock

Immediately prior to the closing of the IPO on January 29, 2018, all outstanding shares of preferred stock were automatically converted into an aggregate of 4,640,241 shares of the Company’s common stock.

2018 Omnibus Stock Incentive Plan

On March 6, 2018, the Company’s Board of Directors approved the 2018 Omnibus Stock Incentive Plan (“2018 Plan”). The 2018 Plan provides for the issuance of incentive stock options, nonstatutory stock options, rights to purchase common stock, stock appreciation rights, restricted stock and restricted stock units to employees, directors and consultants of the Company and its affiliates. The 2018 Plan will be approved and adopted by the Company upon receipt of stockholder approval and shall terminate on the tenth (10th) anniversary of the effective date. The 2018 Plan requires the exercise price of stock options to be greater than or equal to the fair value of the Company’s common stock on the date of grant. There are 750,000 shares of common stock authorized under the 2018 Plan.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Liquidity and Financial Condition [Policy Text Block]

Liquidity and Financial Condition

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

Summary of Significant Accounting Policies — Stock-Based Compensation for additional discussion of the use of estimates in estimating the fair value of the Company’s common stock.

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment, Net

Deferred Charges, Policy [Policy Text Block]

Deferred Offering Costs

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Impairment of Long-lived Assets

Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]

Preferred Stock

Derivatives, Policy [Policy Text Block]

Convertible Instruments

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

Level 1 — quoted prices in active markets for identical assets or liabilities;

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable; and

Level 3 — inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).

Income Tax, Policy [Policy Text Block]

Income Taxes

The Company utilizes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.

The Company’s policy is to classify assessments, if any, for tax-related interest as interest expense and penalties as general and administrative expenses in the statements of operations.

Research and Development Expense, Policy [Policy Text Block]

Research and Development

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Stock-Based Compensation

The March 2017 independent appraisal utilized the option pricing method, or OPM, as the most reliable method with the following steps being applied:

⋅

Establishment of total enterprise or equity value;

⋅

Analysis of equity rights for each class of security;

⋅

Selection of appropriate model for valuation purposes;

⋅

Determination of key valuation inputs; and

⋅

Computation of the fair value of the subject security.

Earnings Per Share, Policy [Policy Text Block]

Net Loss Per Common Share

The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:

	December 31,
	2017		2016
Options		1,684,416		786,667
Warrant		61,875		-
Series A Convertible Preferred Stock		2,932,431		3,232,294
Series A-2 Convertible Preferred Stock		788,827		788,827
Series B Convertible Preferred Stock		918,983		-
Total potentially dilutive shares		6,386,532		4,807,787

Subsequent Events, Policy [Policy Text Block]

Subsequent Events

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Issued Accounting Pronouncements

Recently Adopted Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:

	December 31,
	2017		2016
Options		1,684,416		786,667
Warrant		61,875		-
Series A Convertible Preferred Stock		2,932,431		3,232,294
Series A-2 Convertible Preferred Stock		788,827		788,827
Series B Convertible Preferred Stock		918,983		-
Total potentially dilutive shares		6,386,532		4,807,787

Prepaid Expenses and Other Current Assets (Tables)

12 Months Ended

Dec. 31, 2017

Prepaid Expense and Other Assets [Abstract]

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]

As of December 31, 2017 and 2016, prepaid expenses and other current assets consisted of the following:

	December 31,
	2017		2016
Prepaid research and development expenses	$	28,932	$	-
Prepaid patent expense		7,833
Prepaid insurance expenses		383		2,335
Total prepaid expenses and other current assets	$	37,149	$	2,335

Property and Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2017

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]

As of December 31, 2017 and 2016, property and equipment consisted of the following:

	December 31,
	2017		2016
Equipment	$	34,979	$	24,745
Leasehold improvements		40,000		40,000
		74,979		64,745
Less: accumulated depreciation and amortization		(47,019)		(21,553)
Property and equipment, net	$	27,960	$	43,192

Accrued Expenses and Other Current Liabilities (Tables)

12 Months Ended

Dec. 31, 2017

Payables and Accruals [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

As of December 31, 2017 and 2016, accrued expenses and other current liabilities consisted of the following:

	December 31,
	2017		2016
Accrued research and development expenses	$	120,455	$	61,000
Accrued legal expenses		-		37,597
Accrued rent expense		-		18,590
Accrued professional services		41,831		-
Accrued offering costs		133,000		-
Other		10,977		4,516
Total accrued expenses and other current liabilities	$	306,263	$	121,703

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

The income tax (provision) benefit consists of the following:

	For The Years Ended
	December 31,
	2017		2016
Federal:
Current	$	-	$	-
Deferred		235,473		1,287,931
State and local:				-
Current		-		-
Deferred		80,301		151,521
		315,774		1,439,452
Change in valuation allowance		(315,774)		(1,439,452)
Income tax (provision) benefit	$	-	$	-

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

A reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows:

	For The Years Ended
	December 31,
	2017			2016
Tax benefit at federal statutory rate		34.0	%		34.0	%
State income taxes, net of federal benefit		4.0	%		4.0	%
Incremental research and development credits		6.3	%		2.7	%
Prior period adjustments and other		(8.1)	%		0.0	%
Effect of tax rate changes		(30.0)	%		0.0	%
Change in valuation allowance		(6.2)	%		(40.7)	%
Effective income tax rate		0.0	%		0.0	%

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

The tax effects of temporary differences that give rise to deferred tax assets and liabilities are presented below:

	December 31,
	2017		2016
Deferred Tax Assets:
Net operating loss carryforwards	$	2,588,641	$	2,742,397
Stock-based compensation		347,977		333,066
Research & development tax credits		526,134		201,840
Intangible assets		364,508		234,183
Gross deferred tax assets		3,827,260		3,511,486

Valuation allowance		(3,827,260)		(3,511,486)

Deferred tax assets, net of valuation allowance	$	-	$	-

Changes in valuation allowance	$	(315,774)	$	(1,439,452)

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

Future minimum payments under this operating lease agreement are as follows:

For the Year Ending
December 31,	Amount
2018		33,108
	$	33,108

Stockholders’ Equity (Tables)

12 Months Ended

Dec. 31, 2017

Equity [Abstract]

Schedule Of Warrants Outstanding [Table Text Block]

A summary of the warrant activity during the year ended December 31, 2017 is presented below:

					Weighted
			Weighted		Average
			Average		Remaining		Aggregate
	Number of		Exercise		Life		Intrinsic
	Warrants		Price		In Years		Value
Outstanding January 1, 2017		-	$	-
Granted		61,875		6.98
Forfeited		-		-
Outstanding December 31, 2017		61,875	$	6.98		9.7	$	-

Exercisable December 31, 2017		61,875	$	6.98		9.7	$	-

Warrants Outstanding And Exercisable Exercise Price [Table Text Block]

The following table presents information related to warrants as of December 31, 2017:

Warrants Outstanding				Warrants Exercisable
				Weighted
		Outstanding		Average		Exercisable
Exercise		Number of		Remaining Life		Number of
Price		Warrants		In Years		Warrants
	6.98		61,875		9.7		61,875
			61,875		9.7		61,875

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

In applying the Black-Scholes option pricing model to stock options granted, the Company used the following approximate assumptions:

	For the Year Ended
	December 31,
	2017			2016
Expected term (years)		5.32 - 10.00			10.00
Risk free interest rate		1.95 - 2.39	%		1.53% - 1.83	%
Expected volatility		130	%		131	%
Expected dividends		0.00	%		0.00	%

Share-based Compensation, Stock Options, Activity [Table Text Block]

A summary of the option activity during the year ended December 31, 2017 is presented below:

					Weighted
			Weighted		Average
			Average		Remaining		Aggregate
	Number of		Exercise		Life		Intrinsic
	Options		Price		In Years		Value
Outstanding January 1, 2017		786,669	$	1.37
Granted		897,747		1.95
Forfeited		-		-
Outstanding December 31, 2017		1,684,416	$	1.68		8.5	$	4,361,825

Exercisable December 31, 2017		920,383	$	1.39		7.6	$	883,675

Schedule Of Share Based Compensation Shares Outstanding Under Stock Option Plans By Exercise Price Range [Table Text Block]

The following table presents information related to stock options as of December 31, 2017:

Options Outstanding				Options Exercisable
				Weighted
		Outstanding		Average		Exercisable
Exercise		Number of		Remaining Life		Number of
Price		Options		In Years		Options
$	1.24		760,001		7.2		760,001
$	1.95		897,747		9.5		152,465
$	5.25		26,668		8.8		7,917
			1,684,416		7.6		920,383

Business Organization and Nature of Operations (Details Textual)		12 Months Ended
	Jan. 08, 2018	Dec. 31, 2017
Entity Incorporation, State Country Name		Florida
Entity Incorporation, Date of Incorporation		Mar. 12, 2014
Subsequent Event [Member]
Stockholders' Equity, Reverse Stock Split	1-for-3.75

Summary of Significant Accounting Policies (Details) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,386,532	4,807,787
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	61,875	0
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,684,416	786,667
Series A Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,932,431	3,232,294
Series A-2 Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	788,827	788,827
Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	918,983	0

Summary of Significant Accounting Policies (Details Textual) - USD ($)	1 Months Ended		12 Months Ended
	Jan. 29, 2018	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Mar. 27, 2018
Working capital, Amount			$ 4,734,013
Retained Earnings (Accumulated Deficit)			(19,261,186)	$ (14,131,199)
Cash, Uninsured Amount			4,999,511	3,137,288
Net Income (Loss) Attributable to Parent			(5,129,987)	(3,533,443)
Deferred Offering Costs			$ 328,700	$ 0
Share Price		$ 3.23
Fair Value Inputs, Discount for Lack of Marketability		40.00%
Share Price, at Fair Value		$ 1.95
Minimum [Member]
Property, Plant and Equipment, Useful Life			2 years
Maximum [Member]
Property, Plant and Equipment, Useful Life			5 years
Subsequent Event [Member]
Proceeds from Issuance Initial Public Offering	$ 24,500,000
Share Price					$ 9.20

Prepaid Expenses and Other Current Assets (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Prepaid Expense and Other Assets [Abstract]
Prepaid research and development expenses	$ 28,932	$ 0
Prepaid patent expense	7,833
Prepaid insurance expenses	383	2,335
Total prepaid expenses and other current assets	$ 37,149	$ 2,335

Property and Equipment, Net (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment, Gross	$ 74,979	$ 64,745
Less: accumulated depreciation and amortization	(47,019)	(21,553)
Property and equipment, net	27,960	43,192
Equipment [Member]
Property, Plant and Equipment, Gross	34,979	24,745
Leasehold Improvements [Member]
Property, Plant and Equipment, Gross	$ 40,000	$ 40,000

Property and Equipment, Net (Details Textual) - USD ($)	12 Months Ended
Property and Equipment, Net (Details Textual) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Depreciation, Depletion and Amortization	$ 25,466	$ 12,802

Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Accrued research and development expenses	$ 120,455	$ 61,000
Accrued legal expenses	0	37,597
Accrued rent expense	0	18,590
Accrued professional services	41,831	0
Accrued offering costs	133,000	0
Other	10,977	4,516
Total accrued expenses and other current liabilities	$ 306,263	$ 121,703

Income Taxes (Details) - USD ($)	12 Months Ended
Income Taxes (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Federal:
Current	$ 0	$ 0
Deferred	235,473	1,287,931
State and local:
Current	0	0
Deferred	80,301	151,521
Income Tax Expense Benefit Before Adjustments for Change in Valuation Allowance	315,774	1,439,452
Change in valuation allowance	(315,774)	(1,439,452)
Income tax (provision) benefit	$ 0	$ 0

Income Taxes (Details 1)	12 Months Ended
Income Taxes (Details 1)	Dec. 31, 2017	Dec. 31, 2016
Tax benefit at federal statutory rate	34.00%	34.00%
State income taxes, net of federal benefit	4.00%	4.00%
Incremental research and development credits	6.30%	2.70%
Prior period adjustments and other	(8.10%)	0.00%
Effect of tax rate changes	(30.00%)	0.00%
Change in valuation allowance	(6.20%)	(40.70%)
Effective income tax rate	0.00%	0.00%

Income Taxes (Details 2) - USD ($)	12 Months Ended
Income Taxes (Details 2) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Deferred Tax Assets:
Net operating loss carryforwards	$ 2,588,641	$ 2,742,397
Stock-based compensation	347,977	333,066
Research & development tax credits	526,134	201,840
Intangible assets	364,508	234,183
Gross deferred tax assets	3,827,260	3,511,486
Valuation allowance	(3,827,260)	(3,511,486)
Deferred tax assets, net of valuation allowance	0	0
Changes in valuation allowance	$ 315,774	$ 1,439,452

Income Taxes (Details Textual) - USD ($)	12 Months Ended
Income Taxes (Details Textual) - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Operating Loss Carryforwards		$ 11,000,000	$ 7,200,000
Operating loss carryforwards expiration term		2034 to 2037
Tax Credit Carryforward, Limitations on Use		In accordance with Section 382 of the Internal Revenue Code, the usage of the Company's net operating loss carry forwards could become subject to annual limitations if there are greater than 50% ownership changes.
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		34.00%	34.00%
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount		$ 1,500,000
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount		$ 1,500,000
Maximum [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		35.00%
Domestic Tax Authority [Member]
Operating Loss Carryforwards		$ 2,000,000
Scenario, Plan [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%

Commitments and Contingencies (Details)	Dec. 31, 2017 USD ($)
2018	$ 33,108
Operating Leases, Future Minimum Payments Due	$ 33,108

Commitments and Contingencies (Details Textual)	1 Months Ended	12 Months Ended
Commitments and Contingencies (Details Textual)	Sep. 15, 2016 USD ($) a	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Net Rentable Area \| a	953
Operating Leases, Rent Expense, Minimum Rentals	$ 3,895
Lease Expiration Date	Sep. 14, 2018
Lessee, Operating Lease, Renewal Term		2 years
Operating Leases, Rent Expense, Net		$ 45,678	$ 18,590
Loss Contingency, Damages Sought, Value		1,100,000
Malpractice Loss Contingency, Insurance Recoveries		$ 10,000,000

Related Party Transactions (Details Textual)			1 Months Ended			12 Months Ended
Related Party Transactions (Details Textual)	Jul. 07, 2017 $ / shares shares	Jul. 06, 2017 USD ($)	Jan. 29, 2018 USD ($)	Sep. 15, 2016 USD ($) a ft²	Jul. 31, 2016 USD ($)	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 31, 2016 USD ($) $ / shares	Dec. 31, 2015
Research and Development Expense						$ 3,816,732	$ 2,966,165
Minority Interest Ownership Percentage In Company						5.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross \| shares						897,747
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares						$ 1.95
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value \| $ / shares						$ 1.77	$ 1.16
Net Rentable Area \| a				953
Lessee, Operating Lease, Renewal Term						2 years
Related Parties, Ownership Interest Percentage								5.00%
Vice President of Research and Development [Member]
Research and Development Expense						$ 1,155,500	$ 1,427,958
Officers Compensation per Month		$ 9,167
Officers Compensation per Hour		175
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross \| shares	100,264
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares	$ 1.95
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	36 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value \| $ / shares	$ 173,900
Net Rentable Area \| ft²				953
Lease, Monthly Base Rent				$ 3,895
Lessee, Operating Lease, Expiry date				Sep. 14, 2018
Lessee, Operating Lease, Renewal Term				2 years
Operating Lease, Expense						45,678	18,590
Security Deposit						3,895
Leasehold Improvements, Gross						40,000
Vice President of Research and Development [Member] \| Subsequent Event [Member]
Officers' Compensation			$ 165,000
Senju Pharmaceutical Co [Member]
Royalty Income, Percentage								5.00%
License Agreement, Expiry Period, Description								The agreement shall continue in full force and effect, on a country-by-country basis, until the latest to occur of: (i) the tenth (10th) anniversary of the first commercial sale of a micro-dose product candidate in Asia; or (ii) the expiration of the licensed patents.
Research and Development Expense [Member] \| Vice President of Research and Development [Member]
Due to Related Parties						94,998
Related to expenses incurred						9,906
Chief Executive Officer [Member]
Office space expenses					$ 3,000
Operating Leases, Rent Expense						36,000	18,000
Cura Partners [Member] \| Consulting Agreement [Member]
Consulting agreement payment, Permonth		9,567
Consulting agreement payment, Perhour		$ 250
Cura Partners [Member] \| General and Administrative Expense [Member] \| Consulting Agreement [Member]
Related Party Transaction, Expenses from Transactions with Related Party						85,835
Private Medical Equity, Inc. [Member]
Consulting Fee						33,200
Private Medical Equity, Inc. [Member] \| Consulting Agreement [Member]
Related Party Transaction, Expenses from Transactions with Related Party						329,400	398,400
Private Medical Equity, Inc. [Member] \| Research and Development Expense [Member] \| Consulting Agreement [Member]
Related Party Transaction, Expenses from Transactions with Related Party						176,344	318,720
Private Medical Equity, Inc. [Member] \| General and Administrative Expense [Member] \| Consulting Agreement [Member]
Related Party Transaction, Expenses from Transactions with Related Party						152,656	79,680
Beneficial Owner [Member] \| Research and Development Expense [Member] \| Consulting Agreement [Member]
Related Party Transaction, Expenses from Transactions with Related Party						$ 0	$ 366,209

Stockholders’ Equity (Details)	12 Months Ended
Stockholders’ Equity (Details)	Dec. 31, 2017 USD ($) $ / shares shares
Number of Warrants, Outstanding \| shares	0
Number of Warrants, Granted \| shares	61,875
Number of Warrants, Forfeited \| shares	0
Number of Warrants, Outstanding \| shares	61,875
Number of Warrants, Exercisable \| shares	61,875
Weighted Average Exercise Price, Outstanding \| $ / shares	$ 0
Weighted Average Exercise Price, Granted \| $ / shares	6.98
Weighted Average Exercise Price, Forfeited \| $ / shares	0
Weighted Average Exercise Price, Outstanding \| $ / shares	6.98
Weighted Average Exercise Price, Exercisable \| $ / shares	$ 6.98
Weighted Average Remaining Life In Years, Outstanding	9 years 8 months 12 days
Weighted Average Remaining Life In Years, Exercisable	9 years 8 months 12 days
Aggregate Intrinsic Value, Outstanding \| $	$ 0
Aggregate Intrinsic Value, Exercisable \| $	$ 0

Stockholders’ Equity (Details 1)	12 Months Ended
Stockholders’ Equity (Details 1)	Dec. 31, 2017 $ / shares shares
Warrants Outstanding, Outstanding Number of Warrants	61,875
Warrants Exercisable, Weighted Average Remaining Life In Years	9 years 8 months 12 days
Warrants Exercisable, Exercisable Number of Warrants	61,875
Exercise Price 6.98 [Member]
Warrants Outstanding, Exercise Price \| $ / shares	$ 6.98
Warrants Outstanding, Outstanding Number of Warrants	61,875
Warrants Exercisable, Weighted Average Remaining Life In Years	9 years 8 months 12 days
Warrants Exercisable, Exercisable Number of Warrants	61,875

Stockholders’ Equity (Details 2)	12 Months Ended
Stockholders’ Equity (Details 2)	Dec. 31, 2017	Dec. 31, 2016
Expected term, Minimum (years)	5 years 3 months 25 days
Expected term, Maximum (years)	10 years
Expected term (years)		10 years
Risk free interest rate, Minimum	1.95%	1.53%
Risk free interest rate, Maximum	2.39%	1.83%
Expected volatility	130.00%	131.00%
Expected dividends	0.00%	0.00%

Stockholders’ Equity (Details 3)	12 Months Ended
Stockholders’ Equity (Details 3)	Dec. 31, 2017 USD ($) $ / shares shares
Number of Options, Outstanding \| shares	786,669
Number of Options, Granted \| shares	897,747
Number of Options, Forfeited \| shares	0
Number of Options, Outstanding \| shares	1,684,416
Number of Options, Exercisable \| shares	920,383
Weighted Average Exercise Price, Outstanding \| $ / shares	$ 1.37
Weighted Average Exercise Price, Granted \| $ / shares	1.95
Weighted Average Exercise Price, Forfeited \| $ / shares	0
Weighted Average Exercise Price, Outstanding \| $ / shares	1.68
Weighted Average Exercise Price, Exercisable \| $ / shares	$ 1.39
Weighted Average Remaining Life In Years, Outstanding	8 years 6 months
Weighted Average Remaining Life In Years, Exercisable	7 years 7 months 6 days
Aggregate Intrinsic Value, Outstanding \| $	$ 4,361,825
Aggregate Intrinsic Value, Exercisable \| $	$ 883,675

Stockholders’ Equity (Details 4)	12 Months Ended
Stockholders’ Equity (Details 4)	Dec. 31, 2017 $ / shares shares
Options Outstanding, Outstanding Number of Options	1,684,416
Options Exercisable, Weighted Average Remaining Life In Years	7 years 7 months 6 days
Options Exercisable, Exercisable Number of Options	920,383
Exercise Price 1.24 [Member]
Options Outstanding, Exercise Price \| $ / shares	$ 1.24
Options Outstanding, Outstanding Number of Options	760,001
Options Exercisable, Weighted Average Remaining Life In Years	7 years 2 months 12 days
Options Exercisable, Exercisable Number of Options	760,001
Exercise Price 1.95 [Member]
Options Outstanding, Exercise Price \| $ / shares	$ 1.95
Options Outstanding, Outstanding Number of Options	897,747
Options Exercisable, Weighted Average Remaining Life In Years	9 years 6 months
Options Exercisable, Exercisable Number of Options	152,465
Exercise Price 5.25 [Member]
Options Outstanding, Exercise Price \| $ / shares	$ 5.25
Options Outstanding, Outstanding Number of Options	26,668
Options Exercisable, Weighted Average Remaining Life In Years	8 years 9 months 18 days
Options Exercisable, Exercisable Number of Options	7,917

Stockholders’ Equity (Details Textual) - USD ($)

1 Months Ended

12 Months Ended

Jan. 08, 2018

Jul. 06, 2017

Oct. 06, 2016

Jan. 29, 2018

Sep. 27, 2017

Dec. 31, 2017

Dec. 31, 2016

Mar. 27, 2018

Jan. 05, 2018

Mar. 31, 2017

Common Stock, Shares Authorized

60,000,000

Common Stock, Par or Stated Value Per Share

$ 0.0001

Preferred Stock, Shares Authorized

36,000,000

Preferred Stock, Par or Stated Value Per Share

$ 0.0001

Preferred stock, prorata allotment, Pecentage

75.00%

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

61,875

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 6.98

Proceeds from Issuance of Warrants

$ 431,574

$ 0

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

$ 1.77

$ 1.16

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost

$ 412,312

$ 2,690

Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options

$ 1,327,224

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

2 years 4 months 24 days

Share Price

$ 3.23

Non-Employee Grants [Member]

Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options

$ 377,816

2014 Equity Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

48,917

Subsequent Event [Member]

Common Stock, Shares Authorized

90,000,000

Preferred Stock, Shares Authorized

6,000,000

Stock Issued During Period, Shares, New Issues

2,730,000

Shares Issued, Price Per Share

$ 10.00

Stockholders' Equity, Reverse Stock Split

1-for-3.75

Share Price

$ 9.20

Subsequent Event [Member] | 2014 Equity Incentive Plan [Member] | Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

1,866,667

Subsequent Event [Member] | 2014 Equity Incentive Plan [Member] | Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

1,733,333

Series A Convertible Preferred Stock [Member]

Preferred Stock Designated Shares

20,000,000

Stock Issued During Period, Shares, New Issues

^[1]

Preferred Stock, Shares Not Participating in Financings

299,863

Preferred stock, prorata allotment, Pecentage

75.00%

Series A2 Convertible Preferred Stock [Member]

Preferred Stock Designated Shares

5,714,286

Stock Issued During Period, Shares, New Issues

788,827

^[1]

788,827

Shares Issued, Price Per Share

$ 5.25

Proceeds from Issuance of Preferred Stock and Preference Stock

$ 4,141,338

Series B Convertible Preferred Stock [Member]

Preferred Stock Designated Shares

10,000,000

Stock Issued During Period, Shares, New Issues

918,983

^[1]

Shares Issued, Price Per Share

$ 6.98

Preferred Stock, Shares Not Participating in Financings

299,863

Convertible Preferred Stock, Terms of Conversion

Payments of Stock Issuance Costs

$ 41,958

$ 0

Net Proceeds From Issuance Of Preferred Stock And Preference Stock

6,367,693

Gross Proceeds From Issuance Of Convertible Preferred Stock

$ 6,409,651

Series A And Series A2 Convertible Preferred Stock [Member]

Convertible Preferred Stock, Terms of Conversion

The SeriesA and SeriesA-2 Convertible Preferred Stock is convertible, at the option of the holder, at any time into shares of common stock on a one-for-one basis. In the event of any issuances by the Company for less than the in-force conversion price, the preferred stock conversion price shall be reduced on a weighted average basis. Each share of preferred stock shall automatically be converted into shares of common stock at the then effective conversion price: (i)immediately prior to the closing of a firm commitment underwritten initial public offering provided that (A) the aggregate offering price, net of underwriters discounts and expenses, is at least $2.00 per share of common stock and (B) the aggregate proceeds of such offering are not less than $20,000,000; or (ii) the date specified by written consent or agreement of the holders of at least 75% of the then outstanding shares of preferred stock.

[1]	Includes gross proceeds of $6,409,651, less issuance costs of $41,958.

Subsequent Events (Details Textual) - Subsequent Event [Member] - USD ($) $ / shares in Units, $ in Millions		1 Months Ended
	Mar. 06, 2018	Jan. 29, 2018
Shares Issued, Price Per Share		$ 10.00
Payment of Financing and Stock Issuance Costs		$ 2.8
Gross Proceeds of Stock Value Issued During Period		$ 27.3
Stock Issued During Period, Shares, New Issues		2,730,000
Net Proceeds from Issuance of Common Stock		$ 24.5
Convertible Preferred Stock, Shares Issued upon Conversion		4,640,241
2018 Omnibus Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Description	shall terminate on the tenth (10th) anniversary of the effective date
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	750,000